Here we set out to investigate and compare the therapeutic effects of virotherapy with un-armed MYXV (i.e., vMyx-M135KO) with a recombinant MYXV armed with the human TNF (i.e., vMyx-hTNF), and also compare the anti-cancer efficacy of delivering virus systemically via retro-orbital (r.o.)injection of naked virus versus autologous BM ex vivo loaded with each of the above MYXV constructs alone or in combination with chemo/immunotherapy using the transplantable murine Vk*MYC multiple myeloma model. This evidence concerns the gene TNF and plasma cell myeloma.